Company Performance Metrics
- Earl May: Vice President of Lead Discovery
- William Sellers: Co-Founder and BoD Member
Civetta Therapeutics is a cancer therapeutics company to advance new medicines through small molecule targeting of beta-propeller domains. The company leverages small molecule targeting of beta-propeller domains to develop important therapeutics for cancers and other diseases. It also develops a broad range of expertise in drugging the propeller
domains, spanning from biochemistry to biology to medicinal chemistry
Propeller proteins are structural scaffolds that mediate protein-protein interactions of unique substrates. These proteins are found ubiquitously across cell types and can have diverse functional roles in the pathogenesis of cancer, neurodegeneration, metabolic disease, and other areas.
Their vision is to build a portfolio of therapeutics by integrating a broad range of expertise in drugging the propeller domains spanning from biochemistry to biology to medicinal chemistry. These efforts will support the creation of near term therapeutics and longer-term value in becoming a leader in this space.
Civetta Therapeutics was founded in 2019 and is based in Cambridge, Massachusetts, United States.
